Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy
ICIs in combination with bevacizumab can not only improve the patient's prognosis but also yield safe and controllable adverse drug reactions in patients suffering from MSS/pMMR advanced CRC after failure to a 1<sup>st</sup>-line therapy.
Authors
- Xiao-Qian Chen
- Yushuang Luo (ORCID: https://orcid.org/0000-0001-9678-8004)
- Xinfu Ma
- Yong-Zhi Diao
- Qijing Guo
- Liang Wang (ORCID: https://orcid.org/0000-0001-5224-8647)
Institutions
- Qinghai University (CN)
- Qinghai University Affiliated Hospital (CN)
- Qinghai No.3 People's Hospital (CN)
Publication Details
- Journal
- World Journal of Gastrointestinal Surgery
- Published
- 2024-09-27
- DOI
- https://doi.org/10.4240/wjgs.v16.i10.3277
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28